Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2023

Open Access 01-12-2023 | Hyperglycemia | Research

High triglyceride-glucose index and stress hyperglycemia ratio as predictors of adverse cardiac events in patients with coronary chronic total occlusion: a large-scale prospective cohort study

Authors: Yanjun Song, Kongyong Cui, Min Yang, Chenxi Song, Dong Yin, Qiuting Dong, Ying Gao, Kefei Dou

Published in: Cardiovascular Diabetology | Issue 1/2023

Login to get access

Abstract

Background

The triglyceride-glucose (TyG) index and the stress hyperglycaemia ratio (SHR) are both positively associated with cardiovascular (CV) risk in patients with coronary heart disease. However, the prognostic value of these two biomarkers has not been well elucidated in patients with chronic total occlusion (CTO). Therefore, this study aims to evaluate the association of the TyG index and the SHR with long-term prognosis in patients with CTO.

Methods

This prospective cohort study consecutively included 2740 angina patients with CTO from January 2017 to December 2018 at Fuwai Hospital. The outcomes are a composite of CV death and target vessel myocardial infarction (TVMI) and major CV cerebrovascular adverse events (MACCEs, including all-cause death, nonfatal MI, ischaemia-driven target vessel revascularization, and stroke). The association between biomarkers and prognosis was analysed by multivariable Cox proportional hazard models, and the predictive value was determined by a receiver-operating characteristic (ROC) curve.

Results

During the follow-up with a median time of 3 years, 179 (6.5%) cases of MACCEs and 47 (1.7%) cases of CV death or TVMI were recorded. Patients with a high TyG index (> 9.10) and a high SHR (> 0.87) showed a significantly increased risk of CV death/TVMI (TyG index: HR 4.23, 95% CI 1.58–11.37; SHR: HR 5.14, 95% CI 1.89–13.98) and MACCEs (TyG index: HR 2.47, 95% CI 1.54–3.97; SHR: HR 2.91, 95% CI 1.84–4.60) compared with those with a low Tyg index and a low SHR (TyG < 8.56, SHR < 0.76). The area under the curve (AUC) values were 0.623 (TyG index) and 0.589 (SHR) for CV death/TVMI and 0.659 (TyG index) and 0.624 (SHR) for MACCEs. Furthermore, patients with both a high TyG index and a high SHR showed the highest risk of clinical outcomes among patients with different levels of these two biomarkers, and the AUC for the TyG-SHR combination was larger than the TyG index alone in predicting MACCE risk.

Conclusions

The study revealed that a high TyG index and a high SHR were significantly correlated with poor prognosis in patients with CTO and suggested that these two biomarkers are reliable in predicting long-term prognosis in CTO patients.
Appendix
Available only for authorised users
Literature
1.
Khatri JJ. Clinically meaningful definition of myocardial injury after chronic total occlusion intervention. JACC Cardiovasc Interv. 2019;12(19):1924–6.CrossRefPubMed
2.
Azzalini L, Karmpaliotis D, Santiago R, Mashayekhi K, Di Mario C, Rinfret S, Nicholson WJ, Carlino M, Yamane M, Tsuchikane E, et al. Contemporary issues in chronic total occlusion percutaneous coronary intervention. JACC Cardiovasc Interv. 2022;15(1):1–21.CrossRefPubMed
3.
Park TK, Lee SH, Choi KH, Lee JM, Yang JH, Song YB, Hahn JY, Choi JH, Gwon HC, Lee SH, et al. Late survival benefit of percutaneous coronary intervention compared with medical therapy in patients with coronary chronic total occlusion: A 10-year follow-up study. J Am Heart Assoc. 2021;10(6): e019022.CrossRefPubMedPubMedCentral
4.
Sánchez-García A, Rodríguez-Gutiérrez R, Mancillas-Adame L, González-Nava V, Díaz González-Colmenero A, Solis RC, Álvarez-Villalobos NA, González-González JG. Diagnostic accuracy of the triglyceride and glucose index for insulin resistance: a systematic review. Int J Endocrinol. 2020;2020:4678526.CrossRefPubMedPubMedCentral
5.
Roberts GW, Quinn SJ, Valentine N, Alhawassi T, O’Dea H, Stranks SN, Burt MG, Doogue MP. relative hyperglycemia, a marker of critical illness: introducing the stress hyperglycemia ratio. J Clin Endocrinol Metab. 2015;100(12):4490–7.CrossRefPubMed
6.
Xiong S, Chen Q, Long Y, Su H, Luo Y, Liu H, Chen Y, Feng Q, Peng X, Jiang M, et al. Association of the triglyceride-glucose index with coronary artery disease complexity in patients with acute coronary syndrome. Cardiovasc Diabetol. 2023;22(1):56.CrossRefPubMedPubMedCentral
7.
Mone P, Lombardi A, Salemme L, Cioppa A, Popusoi G, Varzideh F, Pansini A, Jankauskas SS, Forzano I, Avvisato R, et al. Stress hyperglycemia drives the risk of hospitalization for chest pain in patients with ischemia and nonobstructive coronary arteries (INOCA). Diabetes Care. 2023;46(2):450–4.CrossRefPubMed
8.
Zhang Y, Song H, Bai J, Xiu J, Wu G, Zhang L, Wu Y, Qu Y. Association between the stress hyperglycemia ratio and severity of coronary artery disease under different glucose metabolic states. Cardiovasc Diabetol. 2023;22(1):29.CrossRefPubMedPubMedCentral
9.
Li Y, He S, Wu Z, Li W, Jian W, Cheng Z, Wang C, Shi Y, Liu J. The predictive value of the triglyceride-glucose index for cardiovascular events in patients with coronary chronic total occlusion. Cardiovasc Diabetol. 2022;21(1):149.CrossRefPubMedPubMedCentral
10.
Mashaly A, Rha SW, Choi BG, Baek MJ, Ryu YG, Choi SY, Byun JK, Li H, Shim MS, Jang WY, et al. Impact of diabetes mellitus on 5-year clinical outcomes in patients with chronic total occlusion lesions. Coron Artery Dis. 2018;29(2):119–26.CrossRefPubMed
11.
Guerrero-Romero F, Simental-Mendia LE, Gonzalez-Ortiz M, Martinez-Abundis E, Ramos-Zavala MG, Hernandez-Gonzalez SO, Jacques-Camarena O, Rodriguez-Moran M. The product of triglycerides and glucose, a simple measure of insulin sensitivity comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95(7):3347–51.CrossRefPubMed
12.
Fu R, Cui K, Yang J, Xu H, Yin D, Song W, Wang H, Zhu C, Feng L, Wang Z, et al. Fasting stress hyperglycemia ratio and in-hospital mortality after acute myocardial infarction in patients with different glucose metabolism status: results from China acute myocardial infarction registry. Diabetes Res Clin Pract. 2023;196: 110241.CrossRefPubMed
13.
Diabetes American. 2 Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(13):27.
14.
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.CrossRefPubMed
15.
Rabar S, Harker M, O’Flynn N, Wierzbicki AS, Guideline Development G. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ. 2014;349: g4356.CrossRefPubMed
16.
Yang E, Spragg D, Schulman S, Gilotra NA, Kilic A, Salenger R, Whitman G, Metkus TS. Rate versus rhythm control in heart failure patients with post-operative atrial fibrillation after cardiac surgery. J Cardiac Fail. 2021;27(8):915–9.CrossRef
17.
Chang YS, Li YH, Lee IT. A synergistic effect of variability in estimated glomerular filtration rate with chronic kidney disease on all-cause mortality prediction in patients with type 2 diabetes: a retrospective cohort study. Cardiovasc Diabetol. 2021;20(1):209.CrossRefPubMedPubMedCentral
18.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Writing Group on the Joint ESCAAHAWHFTFftUDoMI, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551–67.CrossRefPubMed
19.
Alizargar J, Bai CH, Hsieh NC, Wu SV. Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients. Cardiovasc Diabetol. 2020;19(1):8.CrossRefPubMedPubMedCentral
20.
Tao LC, Xu JN, Wang TT, Hua F, Li JJ. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21(1):68.CrossRefPubMedPubMedCentral
21.
Ding X, Wang X, Wu J, Zhang M, Cui M. Triglyceride-glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies. Cardiovasc Diabetol. 2021;20(1):76.CrossRefPubMedPubMedCentral
22.
Guo X, Shen R, Yan S, Su Y, Ma L. Triglyceride-glucose index for predicting repeat revascularization and in-stent restenosis in patients with chronic coronary syndrome undergoing percutaneous coronary intervention. Cardiovasc Diabetol. 2023;22(1):43.CrossRefPubMedPubMedCentral
23.
Zhang R, Shi S, Chen W, Wang Y, Lin X, Zhao Y, Liao L, Guo Q, Zhang X, Li W, et al. Independent effects of the triglyceride-glucose index on all-cause mortality in critically ill patients with coronary heart disease: analysis of the MIMIC-III database. Cardiovasc Diabetol. 2023;22(1):10.CrossRefPubMedPubMedCentral
24.
Lin XL, Li QY, Zhao DH, Liu JH, Fan Q. A high triglyceride-glucose index associated with adverse cardiovascular events in patients with type 2 diabetes mellitus and chronic total occlusion after percutaneous coronary intervention. J Invest Med Off Publ Am Fed Clin Res. 2023. https://​doi.​org/​10.​1177/​1081558923115282​3.CrossRef
25.
Worthley MI, Holmes AS, Willoughby SR, Kucia AM, Heresztyn T, Stewart S, Chirkov YY, Zeitz CJ, Horowitz JD. The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration. J Am Coll Cardiol. 2007;49(3):304–10.CrossRefPubMed
26.
Yang J, Zheng Y, Li C, Gao J, Meng X, Zhang K, Wang W, Shao C, Tang YD. The impact of the stress hyperglycemia ratio on short-term and long-term poor prognosis in patients with acute coronary syndrome: insight from a large cohort study in Asia. Diabetes Care. 2022;45(4):947–56.CrossRefPubMed
27.
Xu W, Yang YM, Zhu J, Wu S, Wang J, Zhang H, Shao XH. Predictive value of the stress hyperglycemia ratio in patients with acute ST-segment elevation myocardial infarction: insights from a multi-center observational study. Cardiovasc Diabetol. 2022;21(1):48.CrossRefPubMedPubMedCentral
28.
Zhou Y, Liu L, Huang H, Li N, He J, Yao H, Tang X, Chen X, Zhang S, Shi Q, et al. ’Stress hyperglycemia ratio and in-hospital prognosis in non-surgical patients with heart failure and type 2 diabetes. Cardiovasc Diabetol. 2022;21(1):290.CrossRefPubMedPubMedCentral
29.
Abdu FA, Galip J, Qi P, Zhang W, Mohammed AQ, Liu L, Yin G, Mohammed AA, Mareai RM, Jiang R, et al. Association of stress hyperglycemia ratio and poor long-term prognosis in patients with myocardial infarction with non-obstructive coronary arteries. Cardiovasc Diabetol. 2023;22(1):11.CrossRefPubMedPubMedCentral
30.
Xu W, Song Q, Wang X, Zhao Z, Meng X, Xia C, Xie Y, Yang C, Guo Y, Zhang Y, et al. Association of stress hyperglycemia ratio and in-hospital mortality in patients with coronary artery disease: insights from a large cohort study. Cardiovasc Diabetol. 2022;21(1):217.CrossRefPubMedPubMedCentral
31.
Cui K, Fu R, Yang J, Xu H, Yin D, Song W, Wang H, Zhu C, Feng L, Wang Z, et al. Stress hyperglycemia ratio and long-term mortality after acute myocardial infarction in patients with and without diabetes: a prospective, nationwide, and multicentre registry. Diabetes Metab Res Rev. 2022;38(7): e3562.CrossRefPubMed
32.
Jeong S, Lee JH. The verification of the reliability of a triglyceride-glucose index and its availability as an advanced tool. Metab Off J Metab Soc. 2021;17(11):97.
33.
Esposito K, Marfella R, Giugliano D. Stress hyperglycemia, inflammation, and cardiovascular events. Diabetes Care. 2003;26(5):1650–1.CrossRefPubMed
34.
Tajstra M, Pyka Ł, Gorol J, Pres D, Gierlotka M, Gadula-Gacek E, Kurek A, Wasiak M, Hawranek M, Zembala MO, et al. Impact of chronic total occlusion of the coronary artery on long-term prognosis in patients with ischemic systolic heart failure: insights from the COMMIT-HF registry. JACC Cardiovasc Interv. 2016;9(17):1790–7.CrossRefPubMed
35.
Güzel T, Aktan A, Demir M, Özbek M, Aslan B. Relationship between contrast-induced nephropathy and long-term mortality after percutaneous coronary intervention in patients with chronic coronary total occlusion. Rev Assoc Med Bras. 2022;68(8):1078–83.CrossRefPubMedPubMedCentral
36.
Aktürk E, Aşkın L, Taşolar H, Kurtoğlu E, Türkmen S, Tanrıverdi O, Uzel KE. Evaluation of contrast nephropathy in percutaneous treatment of chronic total occlusions. Int Med Appl Sci. 2019;11(2):95–100.
37.
Metadata
Title
High triglyceride-glucose index and stress hyperglycemia ratio as predictors of adverse cardiac events in patients with coronary chronic total occlusion: a large-scale prospective cohort study
Authors
Yanjun Song
Kongyong Cui
Min Yang
Chenxi Song
Dong Yin
Qiuting Dong
Ying Gao
Kefei Dou
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2023
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-023-01883-8

Other articles of this Issue 1/2023

Cardiovascular Diabetology 1/2023 Go to the issue

Research

Association between the insulin resistance and all-cause mortality in patients with moderate and severe aortic stenosis: a retrospective cohort study

Research

Prognostic implication of stress hyperglycemia in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Research

The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study

Correction

Correction: Comparison of 2‑year mortality according to obesity in stabilized patients with type 2 diabetes mellitus after acute myocardial infarction: results from the DIAMOND prospective cohort registry

Research

GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease

Research

Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits